Malignant hyperthermia

Postgraduate Medical Journal

Volumn 74, Issue 867, 1998, Pages 11-17

  Abraham, Ron Ben ^a  

^a NONE   (Israel)

Author keywords

Dantrolene; Malignant hyperthermia

Indexed keywords

ANESTHETIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BICARBONATE; CAFFEINE; CARBON DIOXIDE; DANTROLENE; ETOMIDATE; FUROSEMIDE; GLUCOSE; HALOTHANE; INSULIN; KETAMINE; MANNITOL; NEUROMUSCULAR BLOCKING AGENT; NITROUS OXIDE; OPIATE; PROCAINAMIDE; PROPOFOL; PROPRANOLOL; SUXAMETHONIUM;

ANESTHESIA; BREATH ANALYSIS; CLINICAL FEATURE; CORE TEMPERATURE; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; EXTUBATION; HUMAN; HYPERMETABOLISM; MALIGNANT HYPERTHERMIA; PATHOPHYSIOLOGY; PATIENT MONITORING; PREMEDICATION; REVIEW; RHABDOMYOLYSIS;

EID: 0031983278     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.74.867.11     Document Type: Review

References (5)

1. Denborough MA, Lovell RRH. Anaesthetic deaths in a family. Lancet 1960;2:45-55.
2. Krivosic-Horber RM, Adnet PJ. L'hyperthermie maligne anaesthesique: un syndrome dont le taux de mortalite est inacceptable. La revue du Praticien. Med Genet 1992;188:50-8.
3. Strazis KP, Fox AW. Malignant hyperthermia: a review of published cases. Anesth Analg 1993; 77:297-304.
4. Britt BA. Malignant hyperthermia. Can Anaesth Soc J 1985;32:666-77.
5. Harrison GG. Dantrolene-dynamics and kinetics. BrJ Anaesth 1988;60:274-86.